Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ibrutinib + SEL24-B489|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ibrutinib||Imbruvica||PCI-32765||BTK inhibitor 22 EGFR Inhibitor (Pan) 47 HER2 Inhibitor 25||Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is FDA approved for use in patients with mantle cell lymphoma, CLL/SLL and CLL/SLL with del 17p, Waldenstroem’s macroglobulinemia, marginal zone lymphoma, and in combination with Rituxan (rituximab) for untreated CLL/SLL (FDA.gov).|
|SEL24-B489||SEL24|SEL 24|MEN1703|MEN-1703||FLT3 Inhibitor 55 PIM Inhibitor (Pan) 9||SEL24-B489 (MEN1703) is an inhibitor of PIM kinases 1, 2, 3, and FLT3, which may suppress cell growth and induce apoptosis (Blood 126 (23):706.December 2015, PMID: 29682194).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||diffuse large B-cell lymphoma||not applicable||Ibrutinib + SEL24-B489||Preclinical||Actionable||In a preclinical study, SEL24-B489 demonstrated a synergistic effect when combined with Ibruvica (ibrutinib) in diffuse large B-cell lymphoma cells in culture, resulting in cell growth inhibition ((Blood 126 (23):706.December 2015).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|